API Holdings Limited (PharmEasy) Unlisted Shares

API Holdings Limited (PharmEasy) Company Overview:

API Holdings Limited is the largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021) which through custom-built technology platform and supply chain capabilities, operates an integrated and end-to-end interconnected network business serving the healthcare needs of stakeholders.

Progress till now:

The founders started Dialhealth, a consumer pharmaceutical delivery service in Mumbai where they realized the supply chain issues. As a result, they founded ascent in 2013 which distributed pharma products to pharmacies where they built strong supply chain capabilities. After building strong supply chain capabilities in 2015, founders built a pharmeasy marketplace. They acquired docon in 2016 which provides EMR and clinic management service along with teleconsultation offerings. The company built retailio to accelerate technology adoption and to expand supply chain capabilities beyond pharmacies. In 2020, all businesses were consolidated into API holdings to create an integrated digital healthcare platform. In 2021, they acquired medlife, aknamed, and thyrocare. They also acquired a 49% stake in Marg.

With these acquisitions, the company now touches every stakeholder involved in healthcare – consumers, doctors, laboratories, and hospitals.

Key Milestones as per report of 2024 are as under:

The key milestones were:
• The Company increased the number of labs accredited by the National Accreditation
Board for Testing and Calibration Laboratories (“NABL”) from 15 to 25.
• In March 2024, approximately 95% of total samples were processed in NABLaccredited labs.
• The Company conducted around 147 million tests, representing a 4% year-on-year
growth.
• For the purpose of these tests, around 22 million samples were processed, indicating
an 8% year-on-year growth in samples processing.
• The Company’s active franchisee base increased to over 7,900, more than doubled in
the last three years.
Marketplace to avail diagnostics services offered by our brand PharmEasy Labs.
PharmEasy Labs recorded revenues of INR 1,164.76 million in Fiscal 2024.

Other services including fulfilment (services to customer for pharmaceutical and OTC
products sold on PharmEasy marketplace) and technology services, software services for
doctors and pharmacies and Retailio technology generated revenue of INR 433.28 million
in Fiscal 2024.
Retailio provides technology which enables wholesalers and pharmacies to connect and
sell a wide range of pharma and other medical products. It is available as a mobile app
and web application. For the month of March 2024, 109,028 pharmacies and 3,272
wholesalers used Retailio to fulfil their procurement needs.

Board of directors of the company:

Past performance of the company:

(All figures INR in crores except EPS data)

The company issued 10 bonus shares for every share held on 28^th October 2021 and also sub-divided equity shares from FV 10 to FV 1.

API Holdings Limited 2024

API-Holdings-Limited-2024.pdf

Company details:

Unlisteddeal review:

• The company has a strong product portfolio and huge distribution network, which has benefited the API Holdings Limited (PharmEasy) share price.
• The overall market size is growing which will benefit the company.
• The recent acquisitions have resulted in the company being able to provide end-to-end solutions which are expected to increase the customer base of the company.

API Holdings Limited in the news:

• PharmEasy Rights Issue: Epharmacy Raises INR 1,804 Cr At A 90% Valuation Cut:
• Exclusive | Aditya Puri joins board of PharmEasy’s parent API Holdings ahead of IPO: https://www.moneycontrol.com/news/business/exclusive-aditya-puri-joins-board-of-pharmeasys-parent-api-holdings-ahead-of-ipo-6977151.html

Frequently Asked Questions (FAQs) on API Holdings Limited (PharmEasy) Unlisted Shares: